http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2666144-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d63f33f45efa5c1c0e0292ba2dcb972b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-472 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472 |
| filingDate | 2014-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22274a623996ee1df28d57d57bc09e1b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91a64d87e7b14d1485f26d6c24e8e59a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5647bc3f503056ed3b2acb0af9ed545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a15331b1cd3aa7140d589409af175ea0 |
| publicationDate | 2018-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2666144-C2 |
| titleOfInvention | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
| abstract | FIELD: chemistry. n SUBSTANCE: invention relates to organic chemistry, namely, to a crystalline formof {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid (Compound A), characterized by having an X-ray powder diffractogram comprising at least one peak selected from 8.1, 10.6, 11.5, 14.5, 16.2, 19.3, 21.5, 21.9, 22.7, 24.5 and 26.6 °2θ ± 0.2 °2θ, determined on a diffractogram using Cu-Καradiation, as well as to a pharmaceutical composition comprising said form, method for treating a condition associated with hypoxia inducible factor (HIF), method for treating a condition associated with erythropoietin (EPO), method of treating anemia, a method for preparing the crystalline form of Compound A. Compound A. n EFFECT: obtained is a novel crystalline form of compound A, which is characterized by thermodynamic stability, which provides a number of advantages in manufacturing and preparing formulations therewith. n 15 cl, 12 dwg, 2 tbl, 9 ex |
| priorityDate | 2013-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 104.